Pharmalicensing.com: Reports database: Report searching

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd

Report search

Bristol-Myers Squibb Pharmaceutical Company Intelligence Report

Espicom Healthcare Intelligence - 5/31/2006

Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Headquartered in New York, Bristol-Myers Squibb (BMS) is involved in the research and development of treatments for conditions such as heart disease, high blood pressure, stroke, diabetes, cancer, HIV/AIDS, depression, schizophrenia and pain. The company’s research and development efforts are principally focused on Oncology, Affective (Psychiatric) Disorders and Metabolics.

Current Growth Drivers
Plavix (clopidogrel), a platelet aggregation inhibitor, is BMS’ largest selling product and continues to make substantial year-on-year sales growth. The product benefits from co-development and co-commercialisation with sanofi-aventis in a number of markets worldwide. Since its first approval in 1997, Plavix has been prescribed for around 48 million patients.

Similarly, Avapro/Avalide (irbesartan), an angiotensin II receptor agonist indicated for the treatment of hypertension and diabetic neuropathy, was co-developed and co-marketed with sanofi-aventis in several markets and also has demonstrated steady market gains since its launch.

Abilify (aripiprazole), indicated for the treatment of schizophrenia and related conditions, is the company’s flagship Affective Disorders product. The product was licensed from Otsuka, with whom BMS co-promotes Abilify in several markets, and has made strong sales increases since it became part of BMS’ product portfolio.

Erbitux (cetuximab) was licensed from ImClone Systems to become BMS’ first biological product. It is used in the treatments of various cancers and in March 2006, it became the first new treatment for squamous cell head and neck cancer in nearly three decades.

Reyataz (atazanavir), a potent azapeptide inhibitor of HIV protease, is the first once-daily protease inhibitor to be approved by the FDA. In 2005, it demonstrated the most significant growth of BMS’ pharmaceutical products, with sales increasing by nearly 70 per cent from the previous year.

Latest Results
EXECUTIVE SUMMARY: Introduction; Financial Performance 2005; Company Strategy; Product / R&D Overview; Conclusions
PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT: Cardiovascular - Products; Cardiovascular - R&D; Cardiovascular - Summary; Virology - Products; Virology - R&D; Virology - Summary; Oncology - Products; Oncology - R&D; Affective Disorders - Products; Affective Disorders - R&D; Affective Disorders - Summary; Metabolics - Products; Metabolics - R&D; Metabolics - Summary; Others - Products; Others - R&D
APPENDIX 1 - FINANCIAL PERFORMANCE: Full Year Results 2005
APPENDIX 2 - KEY CORPORATE EVENTS
APPENDIX 3 - KEY AGREEMENTS: Adenosine Therapeutics LLC; Ariad Pharmaceuticals Inc; Celltech Chiroscience; Celltrion Inc; Chiron Corporation; Domantis Inc; Elan Corporation Plc; Elixir Pharmaceuticals; Exelixis Inc; Genzyme Transgenics Corp (GTC); Gilead Sciences Inc; GPC Biotech Inc; ImClone Systems; Intra-Cellular Therapies Inc (ICT); Janssen/Neurocrine Biosciences Inc; Kyorin Pharmaceutical Co Ltd; Lexicon Genetics Incorporated; Medarex Inc; Merck & Co; Merck Santé SAS; Nerviano Medical Sciences; Novartis; Otsuka/Taiho Pharmaceutical Co Ltd; OXIGENE Inc; Pierre Fabre Médicament; sanofi-aventis; Shionogi; Solvay; Spectrum Pharmaceuticals Inc; Sunesis Pharmaceuticals; Licensing; Co-promotion/Co-marketing

Discontinued Agreements

Corgentech Inc; Flamel Technologies SA; Merck & Co; Qdose
APPENDIX 4 - INFRASTRUCTURE: Research and Development Facilities; Manufacturing Facilities
APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES: Subsidiaries; Joint-Venture Companies
APPENDIX 6 - PRODUCT INDEX
INDEX OF TABLES: Principal Operating Results; Capital Expenditure By Business Area; Sales By Business Segment; Operating Income By Business Segment; Year-End Assets By Business Segment; Sales By Geographic Area; Year-End Assets By Geographic Area; Recent Product Launches; Recent Product Approvals; Key R&D Projects; Major Products, Therapeutic Areas and Sales; R&D Pipeline; Major Launched Products; Major Launched Products; Major Launched Products; Major Launched Products; Major Launched Products; Major North American Subsidiaries; Major European Subsidiaries; Major South American Subsidiaries; Major Asia/Pacific Region Subsidiaries
INDEX OF CHARTS: Sales, Costs and Operating Income, 2005; Capital Expenditure By Business Area, 2005; R&D Expenditure and Capital Expenditure; Sales By Business Segment, 2005; Operating Income By Business Segment; Year-End Assets by Business Segment, 2005; Sales By Geographic Area, 2005; Sales of Major Product (2000A-2010E); Top Selling Products, 2005; Avapro/Avalide Sales (2000A-2010E); Plavix/Iscover Sales (2000A-2010E); Pravachol Sales (2000A-2010E); Reyataz Sales (2000A-2010E); Sustiva Sales (2000A-2000E); Zerit Sales (2000A-2010E); Erbitux Sales (2000A-2010E); Taxol Sales (2000A-2010E); Abilify Sales (2000A-2010E); Glucophage Franchise Sales (2000A-2010E); Sales, Costs and Operating Income; Profitability and Research Ratios; R&D Expenditure and Capital Expenditure; Current Assets, Liabilities and Ratio; Assets, Cash and Liquidity; Employees and Productivity

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us